[1]张贤梅 孙勤国 江波 余福安 谢谢 从泽伟.糖松康合剂对糖尿病性骨质疏松大鼠的治疗作用及其对IGF-1和GLP-1表达的影响[J].中国中医骨伤科杂志,2018,26(09):5-8.
 ZHANG Xianmei SUN Qinguo JIANG Bo YU Fuan XIE Xie CONG Zewei.Therapeutic Effect of Tangsongkang Mixture on Diabetic Osteoporosis Rats and Expression of Insulin-like Growth Factor-1 and Glucagon-like Polypeptide-1[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2018,26(09):5-8.
点击复制

糖松康合剂对糖尿病性骨质疏松大鼠的治疗作用及其对IGF-1和GLP-1表达的影响()
分享到:

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第26卷
期数:
2018年09期
页码:
5-8
栏目:
实验研究
出版日期:
2018-09-06

文章信息/Info

Title:
Therapeutic Effect of Tangsongkang Mixture on Diabetic Osteoporosis Rats and Expression of Insulin-like Growth Factor-1 and Glucagon-like Polypeptide-1
文章编号:
1005-0205(2018)09-0005-04
作者:
张贤梅1 孙勤国1 江波1 余福安1 谢谢1 从泽伟1
1武汉大学附属同仁医院(武汉市三医院)(武汉,430060)
Author(s):
ZHANG Xianmei1 SUN Qinguo1 JIANG Bo1 YU Fuan2 XIE Xie1 CONG Zewei1
1Tongren Hospital of Wuhan University,Wuhan 430060,China.
关键词:
糖松康合剂 糖尿病性骨质疏松 胰岛素样生长因子-1 胰高血糖素样多肽-1
Keywords:
Keywords: Tangsongkang mixture diabetic osteoporosis insulin-like growth factor-1 glucagon-like peptide-1
分类号:
R-33
文献标志码:
A
摘要:
目的:探讨糖松康合剂对糖尿病性骨质疏松大鼠的治疗作用及其对胰岛素样生长因子-1(IGF-1)和胰高血糖素样多肽-1(GLP-1)表达的影响。方法:采用高脂饮食联合多次小剂量链脲佐菌素腹腔注射的方法建立糖尿病骨质疏松模型,将模型SD大鼠随机分为3组。模型组(12只)高脂饮食,不给予任何药物; 糖松康组(10只)高脂饮食,糖松康合剂1.6 g/kg灌胃给药; 骨化三醇组(10只)即阳性对照组,高脂饮食,骨化三醇0.04 μg/kg灌胃给药。3组均用甘精胰岛素控制血糖,另设正常对照组(8只),普通饮食,不给予任何药物。检测大鼠体质量、血糖,观察精神、饮食、尿量等一般情况,干预6周后,采血常规检测血钙、血磷、血镁、肝肾功能等生化指标,双能X线检测各组大鼠全身骨密度,ELISA法检测各组IGF-1和GLP-1的表达。结果:较正常组比较,模型组表现明显多饮多食多尿消瘦症状,全身骨密度减低,差异有统计学意义(P=0.045),呈现低钙、低磷、低镁等电解质代谢紊乱现象,IGF-1和GLP-1表达减低,差异有统计学意义(P=0.039,P=0.047); 糖松康组血钙、血磷、血镁含量上升,IGF-1和GLP-1表达较模型组升高,差异有统计学意义(P=0.026,P=0.049),且高于骨化三醇组,差异无统计学意义(P=0.056).结论:糖松康合剂对糖尿病性骨质疏松有一定疗效,且其作用机制与调节IGF-1和GLP-1的表达有关。
Abstract:
Abstract Objective:To investigate the therapeutic effect of Tangsongkang mixture on diabetic osteoporosis rats and the expression of IGF-1 and GLP-1.Methods:Diabetic osteoporosis model was established by intraperitoneal injection of high-fat diet combined with multiple low-dose streptozotocin.Model SD rats were randomly divided into 3 groups:model group(12 rats):high-fat diet,no medication was given; Tangsongkang mixture group(10 rats):high fat-diet,Tangsongkang mixture intragastric administration at 1.6 g/kg; calcitriol group(10 rats),that is,positive control group:high-fat diet,intragastric administration at 0.04 μg/kg.The three groups were treated with insulin glargine to control blood glucose,and normal control group(8 rats):normal diet,no medication was given.The body weight and blood glucose were measured,and the general conditions such as spirit,diet,and urine volume were observed.After 6 weeks of intervention,biochemical parameters such as serum calcium,phosphorus,magnesium,and liver and kidney function were measured by routine blood detection sampling.Dual energy X-ray measurement was performed in each group to examine the bone mineral density of rats.The expression of IGF-1 and GLP-1 was detected by ELISA.Results:Compared with the normal group,the model group showed obvious polydipsia,polyphagia,polyuria and weight loss(P=0.045).It showed electrolyte metabolism disorder such as low calcium,low phosphorus,and low magnesium.The expression of IGF-1 and GLP-1 was decreased(P=0.039,P=0.047,respectively).The levels of serum calcium,phosphorus,and magnesium in the Tangsongkang group increased,and the expressions of IGF-1 and GLP-1 were higher than those in the model group(P=0.026,P=0.049),statistically significant,and higher than the calcitriol group(P=0.056).Conclusion:Tangsongkang Mixture has a certain therapeutic effect on diabetic osteoporosis,and the mechanism of action is related to the expression of IGF-1 and GLP-1.

参考文献/References:

[1] 魏雨田.血清胰岛素样生长因子-1水平与2型糖尿病骨密度的关系[D].唐山:华北理工大学,2017:13-15.
[2] 李晓宇,冯正平.糖尿病性骨质疏松发病机制的研究进展[J].中国骨质疏松杂志,2014,20(5):580-583.
[3] 吴宏梓,方洲,汪少波.中药治疗糖尿病性骨质疏松疗效与安全性的系统评价[J].中国骨质疏松杂志,2016,22(3):251-271.
[4] 梁燕龙,杜敏群,赖文秀,等.2型糖尿病性骨质疏松的鼠类模型的研究进展[J].中国骨质疏松杂志,2016,22(9):1164-1167.
[5] 蒋云霞,李双蕾,陈文辉.2型糖尿病性骨质疏松动物模型建立[J].中国骨质疏松杂志,2015,21(7):894-898.
[6] 冯正平,邓华聪.糖尿病性骨质疏松发病机制的研究进展[J].中国骨质疏松杂志,2012,18(3):281-284.
[7] 尹嘉晶,彭永德.糖尿病与骨质疏松[J].中华内分泌代谢杂志,2014,30(5):449-452.
[8] 黄莹芝,叶山东.糖尿病性骨质疏松的相关危险因素研究进展[J].中国骨质疏松杂志,2016,22(5):647-650.
[9] 杨秋萍.胰高血糖素样肽-1与糖尿病性骨质疏松症[J].昆明医科大学学报,2014,35(9):1-3.
[10] 王一然,翟骁,王奇金.GLP-1 及其类似物对减缓骨质疏松作用的研究进展[J].中国骨质疏松杂志,2015,21(6):752-756.
[11] 管俊,崔瑛.桑寄生药理作用及临床应用研究进展[J].河北中医,2017,39(3):460-462.
[12] 牛银波,潘亚磊,李晨睿,等.续断防治骨质疏松的研究进展[J].中国药理学通报,2013,29(7):892-894.
[13] 蒋俊,崔莉,孙娥,等.基于淫羊藿黄酮类化合物的体内代谢阐述其抗骨质疏松药效物质基础[J].中草药,2014,45(5):721-729.
[14] 李丹丹,江培,杨书美.黄柏的化学成分、药理作用及临床应用研究进展[J].黑龙江医药,2014,27(3):601-605.
[15] 冯果,陈娟,刘文,等.天花粉有效成分及药理活性研究进展[J].微量元素与健康研究,2015,32(6):59-62.

备注/Memo

备注/Memo:
基金项目:武汉市卫生计生办科研计划资助(WZ14A02)
更新日期/Last Update: 2018-09-06